Weiss Ratings Reaffirms “Sell (E+)” Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “sell (e+)” rating reaffirmed by research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen lowered Imunon from a “hold” rating to a “sell” rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $232.50.

Imunon Price Performance

Shares of Imunon stock opened at $5.33 on Wednesday. The company has a market cap of $13.01 million, a PE ratio of -0.41 and a beta of 2.22. Imunon has a 52 week low of $4.70 and a 52 week high of $41.22. The business has a 50 day moving average price of $6.11 and a 200-day moving average price of $11.39.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.